Since HAART was introduced, for HIV-infected patients life expectancy has consistently increased and, for HIV-positive women, this has implied a growing hope of having children. Without antiretroviral therapy, approximately 20-30% of children born to HIV-positive mothers become infected; the rate of infection is directly
Introduction
proportional to the viral activity. In order to maintain viral load as low as possible and to prevent mother-tochild virus transmission, pregnant HIV-positive women are advised to take HAART during pregnancy [1] .
In the past years, a large number of nucleoside reverse transcriptase inhibitors (NRTI)-associated adverse events have been described [2] [3] [4] . Prolonged use of these drugs, in combination with protease inhibitors (PIs), can determine the onset of lipodystrophy, a syndrome characterized by peripheral fat wasting in the face and limbs, accumulation of visceral fat, breast adiposity, cervical fat pads, hyperlipidaemia and insulin resistance [5, 6] . NRTI toxicity is associated with the ability of these drugs to inhibit the activity of DNA polymerase-γ, the enzyme responsible for mitochondrial DNA (mtDNA) replication [7] [8] [9] [10] . Such inhibition can cause a decrease in the number of mtDNA copies, leading to mitochondrial dysfunctions [11] [12] [13] [14] . Depletion of mtDNA in subcutaneous adipose tissue was indeed observed in lipodystrophic patients receiving HAART regimens containing NRTIs [6, [15] [16] [17] ; the decrease in mtDNA content can precede or accompany the clinical manifestations of NRTI-related toxicity [18, 19] .
The effects of NRTIs on mtDNA vary considerably on the basis of the considered drug, with D-drugs such as zalcitabine, stavudine (d4T) and didanosine (ddI) being the most potent [15] . Furthermore, the effects of such drugs vary considerably in different tissues: changes in mtDNA may occur both in fat and peripheral blood mononuclear cells with exposure to ddI, but only in fat with d4T; zidovudine (AZT) can cause mitochondrial myopathy but was not associated with fat or peripheral blood mononuclear cell mtDNA depletion [20] . However, it was found by others that AZT-based HAART recipients can display significant adipocyte mtDNA depletion [21] .
Little is known about the toxic effects of NRTIs on pregnant women, despite the findings that NRTI associated changes in lipid and glucose metabolism can potentially have important consequences on fetal development [22, 23] , and that some disorders, including lactic acidosis and hepatic steatosis, which may have a female preponderance, have been associated with the use of NRTIs [24] .
Use of antiretroviral treatment in pregnancy has been associated with potential risks for the newborn, reduced efficacy of antiretroviral drugs for the mother, increased frequency of adverse effects. It is still unclear if pregnancy itself may affect the incidence of the lactic acidosis/hepatic steatosis syndrome that has been reported for non-pregnant persons taking NRTIs [25] [26] [27] .
Several studies showed that subcutaneous adipose tissue and adipocytes can be altered by HAART, and that such alterations can be evidenced by the quantification of mtDNA [6, 15, 16, 28, 29] . Thus, in order to ascertain if drug toxicity can be observed in pregnant women, we quantified mtDNA content in subcutaneous fat, collected during delivery, from 68 HIV-positive women enrolled in the Italian Prospective Cohort Trial on Efficacy and Toxicity of Antiretroviral in Pregnancy (TARGET) Study, the Italian Prospective Cohort Study designed for investigating the efficacy and toxicity of antiretroviral drugs during pregnancy.
Methods

Participants
This study includes 68 HIV-infected women aged mean ±sd 32.6 ±6.1 years (range 20-46) enrolled in the framework of the TARGET Study.
As established by the study protocol, at the 3rd, 6th and 9th month of pregnancy, blood was collected in all the women to evaluate viroimmunological and metabolic parameters, such as CD4 + T-cell count, plasma viral load, total cholesterol, high-density lipoprotein (HDL), triglycerides (TG) and fasting glucose; analyses were also performed 3, 6 and 9 months after caesarean delivery.
As a control, we studied an age-matched group of 23 HIV-seronegative women who had a caesarean section. A sample of subcutaneous fat (approximately 1 cm 3 ) was surgically removed for mtDNA quantification during the surgical procedure from every woman. In all cases, the biopsy was taken by the senior obstetrician who performed the caesarean section (the same designated operator in each centre), following a wellstandardized protocol. In particular, the sample was taken at the end of the surgical procedure, before finalizing the cutaneous closure just by the middle point.
The specimen was collected without additional reagents and immediately stored at -80°C until use. Ethical approval was obtained at each participating centre and written informed consent was obtained from patients and controls before study entry.
DNA isolation and quantification of mtDNA DNA was extracted from thawed adipose tissue samples using the QIAmp DNA Minikit (QIAgen, Alameda, CA, USA), following instructions supplied by the manufacturer. Intracellular content of mtDNA was measured by real-time PCR using the mtDNA qPCR kit (GeneMoRe Italy srl, Modena, Italy). The assay consists of a multiplexing reaction in which mtDNA and nuclear DNA are quantified simultaneously, as previously described [30] . Each reaction was monitored by the use of a negative control (no template) and a positive control (DNA extract from cells of HepG2 cell line and stored at -20°C in single aliquots), and the efficiency of all reactions based on the slope of a serial dilution of the standard was >95%. The analyses were performed in triplicate and the coefficient of variation of all measures was <15%.
Statistical analysis
The two groups of HIV-positive and HIV-negative women were matched for age by using the MannWhitney U test and the Kruskal-Wallis test was used to compare mtDNA content among different ethnic or CDC groups within the HIV-positive women cohort.
Concerning viroimmunological and metabolic parameters, analyses were performed by ANOVA for repeated measures and by Tukey-Kramer pairwise comparisons. When ANOVA could not be applied, analyses were performed by the Wilcoxon signedrank test for repeated measures. The skewed distribution of clinical parameters required, in some cases, the logarithmic transformation of data.
A linear regression model was used to investigate the effect of the most commonly used drugs on mtDNA content in a joint model that takes into account NRTI and PI backbone simultaneously. The evaluation of possible correlations among mtDNA content, viroimmunological and metabolic parameters was performed by Spearman's correlation test and linear regression analysis to the logarithmic-transformed mtDNA values, adjusted for the most commonly used drugs, in a joint model.
All the above mentioned analyses were performed by using Prism 4.0 (GraphPad Software Inc., La Jolla, CA, USA) and STATA 10.0 software (Statacorp LP, College Station, TX, USA); a P-value <0.05 was considered significant.
Results
Viroimmunological and metabolic parameters of HIV-positive pregnant women
Among the 68 HIV-infected women, ethnicity was distributed as follows: 55.9% Caucasian, 38.2% African, 2.9% Hispanic and 2.9% none of the previous; distribution according to CDC classification was: 26.5% patients in A1 class, 41.2% in A2, 20.6% in A3, 1.5% in B1, 2.9% in B2, 1.5% in B3 and 5.9% in C2.
Patients had taken different therapeutic regimens for a median duration of 5.6 months (range 0.5-95.0); eight regimens were administrated to 55.9% of the cases, whereas other regimens were given to single cases. All the regimens included ≥1 NRTI or nucleotide reverse transcriptase inhibitor. Details on drugs and regimens are reported in Table 1 . It is important to note that 98.5% and 88.2% of patients took lamivudine (3TC) or AZT, respectively (alone, or in combination in the form of Combivir). Consistent with current therapeutic guidelines, 6 or 7 patients took d4T or ddI, respectively. Concerning the use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and PIs, 55.9% patients took nevirapine (NVP), whereas 22.1% or 33.8% took lopinavir/ritonavir (LPV/r) or nelfinavir (NFV), respectively. Data on viroimmunological parameters at different time points during pregnancy and after delivery are shown in Table 2 . During pregnancy, CD4 + T-cell count increased and HIV plasma RNA decreased; these parameters remained constant after delivery.
In parallel with viroimmunological parameters, data concerning metabolic changes were collected. Lipid and glucose analyses were performed every 3 months, during pregnancy and after delivery. Total cholesterol, HDL cholesterol and TG increased significantly during pregnancy and did not change during the 9 months after delivery, whereas fasting glucose remained constant during pregnancy and after delivery.
Quantification of mtDNA
In adipose tissue specimens from HIV-positive pregnant women collected at delivery, we detected a mean ±sd 477.3
±228.4 mtDNA copies per cell (range 102.7-963.4). mtDNA content did not differ among different ethnic groups (categorized as Africans, Caucasians and others; P=0.53), nor among CDC classes (P=0.88). As shown in Figure 1A , when compared with HIV-negative pregnant women, HIV-positive patients had a significantly lower content of mtDNA (P=0.006). In order to study the effect of different regimens on mtDNA content, we stratified patients on the basis of their exposure to different classes of drugs during pregnancy ( Figure 1B) . mtDNA content was similar in patients who took NRTIs only (n=7), NRTIs combined with NNRTIs (n=21), NRTIs combined with NNRTIs and PIs (n=17) or NRTIs combined with PIs (n=20).
The regression analysis performed on the natural log transformed mtDNA values and the most commonly used drugs revealed that ddI/d4T (which were taken, however, by a few patients) were not significantly correlated to a decreased mtDNA content (coefficient =-0.34; P=0.066). After accounting for NRTI backbone, we could note that LPV/r was associated with significantly less mtDNA depletion (coefficient =0.48; P=0.011) compared with NVP, which showed a slight but non-significant correlation with increased mtDNA (coefficient =0.30; P=0.052).
We also evaluated if, at different time points, mtDNA content among HIV-infected women was related to viroimmunological or metabolic parameters (Table 3) . No correlation emerged between mtDNA and CD4 + T-cell count or plasma HIV RNA. Moreover, mtDNA content varied independently from lipid and glucose parameters at the different months, with the exceptions of TG at the 9th month of pregnancy (Spearman's r=-0.409), and of HDL at the 6th month (Spearman's r=0.539).
In order to ascertain the effect of different drugs on the correlation between mtDNA level and metabolic parameters, we performed a linear regression analysis of the natural log transformed mtDNA values, including as covariates the use of an NRTI backbone (that is, the use of 3TC, AZT and ddI/d4T) and the use of the most common drugs (that is, NVP, TDF, LPV/r and NFV).
As evidenced by using the F statistic test, this statistical model could not be applied to the metabolic parameters we have considered, except for HDL at the 6th month and TG at the 9th month of pregnancy. In the first case, a significant correlation emerged between mtDNA content and HDL (coefficient =0.013; P=0.041; Figure 2A) ; when the different drugs were included in the model as covariates, the association between mtDNA and HDL did not show any significant modification (coefficient =0.014; P=0.019). In addition, TG were significantly correlated with mtDNA content (coefficient =-0.001; P=0.015; Figure 2B ); the introduction of covariates revealed that the aforementioned drugs had no effects on this interaction (coefficient =-0.001; P=0.021).
Discussion
The use of antiretroviral therapy for prevention of mother-to-child virus transmission during pregnancy of HIV-positive women has raised some issues regarding the short-and long-term effects of drugs on the mother and the fetus. Thus, the identification of biomarkers detecting their side effects represents an important goal for improving the follow-up of pregnancy. Because several HAART-related pathologies are linked to mitochondrial toxicity, we have measured mtDNA content in pregnant women taking HAART as a marker of adipose tissue damage and alteration of lipid or glucose metabolism [20, [31] [32] [33] [34] . In our study, the values of mtDNA content per cell in subcutaneous fat were similar to what was found, using another technique, in abdominal fat from treated HIV-positive individuals and healthy controls [35] .
As expected, as the consequence of successful treatment, during the 9 months of pregnancy the patients we analysed showed an increase in CD4 + T-cell count and a decrease of HIV RNA plasma level. The increase of CD4 + T-cell count typically observed in the first months of therapy reflects the mobilization of cells from secondary lymphoid tissue. Pregnancy is a particular condition in which the immune system undergoes a sort of physiological suppression, which is crucial to avoid the recognition of the fetus. For this reason, one can hypothesize that the immune reconstitution (that is, the increase in CD4 + T-cell count after HAART) is lower during pregnancy, and could be delayed, even after delivery. Concerning the metabolic profile, we found that while fasting glucose remained stable, lipid parameters increased during pregnancy. This is in agreement with recent studies that have demonstrated that, in HIV-positive women, pregnancy has an important effect on triglyceride and cholesterol values, with a progressive increase from first to third trimester [36, 37] . High levels of TG may cause pancreatitis, induced by severe hypertriglyceridaemia, which has been reported in pregnant women; early hypertriglyceridaemia has been associated with subsequent development of gestational diabetes mellitus or early-onset pre-eclampsia [38] [39] [40] .
HIV-positive cases were all treated with NRTIinclusive regimens and showed significant depletion of adipocyte mtDNA at delivery when compared as a group with untreated seronegative controls. Those cases treated with d4T and/or ddI (n=7) were not significantly different to untreated controls (P=0.066). However, they were also not significantly different to those treated with AZT (n=60). It is likely that these findings reflect the fact that sample size for ddI/d4T-treated women was inadequate to independently detect the association between ddI/d4T and mtDNA depletion, which has been previously reported in other HIV studies.
For ethical reasons we did not study untreated HIVpositive women, and thus the possibility that the differences observed in mtDNA content between patients and controls were due to a direct effect of HIV per se cannot be ruled out.
In this study, we have found an inverse correlation between mtDNA content and TG at 9 months of pregnancy, and a direct correlation between mtDNA content and HDL cholesterol at 6 months of pregnancy, suggesting that possible effects of mtDNA depletion on metabolism could appear after at least 6 months of treatment. It is not clear if this phenomenon is due to direct effects of mtDNA depletion on metabolism, or to physiological changes of the metabolism occurring during pregnancy that affect mtDNA. It remains to be established whether these changes could mask the effect of mtDNA depletion on lipid and glucose metabolism, which usually are not immediate.
Even if PIs, which are commonly used in pregnancy, have an important effect on lipid profile, enhancing the hyperlipidaemic effect of pregnancy [36, 37] , LPV/r or NFV does not affect lipid parameters, even if LPV/r seems to be associated to higher levels of mtDNA. Similarly, TDF, which has been linked to mitochondrial toxicity in cells from renal proximal tubules [41] , but not in peripheral blood CD4 + and CD8 + T-cells [42] , does not contribute to the effect of mtDNA on TG or HDL cholesterol. It must be noted that this result could be influenced by the relative low number of patients taking such drugs, which are not recommended during pregnancy [43] , because of the increased risk for the mother to develop specific adverse events [15, 26] . We are well aware of the limitations of our study, such as the cross-sectional design and the lack of a longitudinal quantification of mtDNA. In any case, we have found a decrease of mtDNA in subcutaneous tissue during pregnancy that could be related to the use of NRTIs. The role of such changes on lipid metabolism is yet to be clarified and deserves further study. 
